Audit: QRS - Curcumin for Health & Longevity
Audit conducted on 02/09/2026 13:46 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol cells, time-to-effect cells, benefit and risk items, gate items, marker rows, targets, why-columns and cadence trace to ER Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications and Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Speculative-tier items are carried at the same certainty; at-a-glance retains “Memory and blood pressure conflict” mirroring the ER Conclusion’s “conflict outright”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications; conflicted outcomes stay in the ER’s own tier; no hedge is upgraded or downgraded. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Stop items come only from the ER’s “Populations who should avoid Curcumin” list; caution items only from the ER’s interaction bullets; no Benefit- or Risk-Modifying Factor is repurposed. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Meriva, Theracurmin and BCM-95 appear with the same doses as the ER Therapeutic Protocol bullet; BioPerine appears exactly as in the ER interaction bullet. No PMIDs, NCT IDs or author names are carried over. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No source, author, organisation or institution is named beyond what the ER attributes. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, non-promotional register matching the ER, including its scepticism about lifespan claims and formulation comparability. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Targets and cadences give the reader actionable structure while the evidence framing stays neutral. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol and monitoring content is stated descriptively (“The range integrative practitioners typically settle at”, “Markers are repeated at 12 weeks”), not as instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives or directives; the footer disclaimer is the template’s own. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should” or comparable directive verbs in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the rendered content. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Acronyms are spelled out throughout (alanine aminotransferase, low-density lipoprotein cholesterol, high-sensitivity C-reactive protein); remaining technical terms are the ER’s own and are load-bearing. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefit and risk tiers are reduced to semicolon-separated headings; gate items are stripped to the key fact. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional (not conventional-laboratory) marker targets and a front-loaded monitoring cadence address exactly this reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nine-marker panel, 24-hour urine collection for stone formers and split dosing are all retained without softening. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No population-level or “if you only do one thing” framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance states the honest ceiling (“Nothing in humans touches lifespan”), and marker rows note headroom depends on raised baselines. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register is used throughout the cards and gates; the deliberately plain wording in At-A-Glance is required by item 7.4 and is the ER Conclusion’s own phrasing. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings verified byte-identical to [qrs_template]. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Full span inventory matches the template; marker_#_* is expanded to marker_1–marker_9 and qualitative_item_# to qualitative_item_1–qualitative_item_8, as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website="evidence_review", website="audit", website="full_review"), the stylesheet link, the CSS block and the footer disclaimer are unchanged from the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section consumed by the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard dose range”, “Absorption-enhanced formulations” and “Half-life and dose splitting” are the ER’s bold labels verbatim; monitoring row labels are the ER Biomarker column verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels are drawn from the ER’s own wording in the “Time to effect” bullet and the corresponding benefit headings, not invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Zero emoji characters in the file; the ER’s ⚠️ Conflicted markers are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than transcribed: gate items strip all mechanistic rationale, example drug lists are trimmed, benefit/risk tiers collapse to single semicolon-separated lines, and the print rules keep the single .sheet container. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; nothing precedes it but the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the descriptive text sits on line 2 before the opener. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is echoed into the body except where a checklist item requires it. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: curcumin_2026-0831-0002_Opus_ER.md (line 4), matching the ER’s own filename frontmatter. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (line 5), matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0902-1316 (line 6). |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: curcumin_2026-0831-0002_Opus_QRS.html (line 9), matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Curcumin for Health & Longevity - Quick Reference Sheet” (line 22); ampersand correctly encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Curcumin for Health & Longevity” (line 417), matching canonical_topic: Curcumin for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0902-1316 → “09/02/2026” (line 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5” (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block is structurally identical to the template; no alternate-names line despite the ER carrying one. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all three Conclusion paragraphs into the decision-relevant signal: what works, what conflicts, what is absent, and the principal harm. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion sentence (pigment/mixed base; knee arthritis vs anti-inflammatory drugs; lipids/glucose/inflammation; memory and blood pressure conflict; no lifespan data; liver injury with concentrated products). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “blood fats”, “blood sugar”, “stomach complaints” and “concentrated products” are used in place of clinical register. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial, author, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from that section’s “Populations who should avoid Curcumin” list. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-list entries are present, in ER order, with none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the stop_items span (lines 575–593). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER em-dash clause is stripped (e.g., “— safety not established…”, “— curcumin contracts the gallbladder by up to 72%…”); no dash-trailing content remains in the span. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “above three times the upper limit of normal”, “above 40 mg”, “within 14 days”, “unless cleared by the treating oncologist” and the haemoglobin thresholds are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies eight such populations and the section is correctly populated, not empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items come from that section’s interaction bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eleven of the ER’s thirteen interaction bullets are carried; the narrow-therapeutic-index CYP3A4 bullet and the CYP3A4/P-glycoprotein cancer-drug bullet are correctly omitted because both are already stop items. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven <li> elements inside the caution_items span (lines 601–620). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “Caution/Monitor/Avoid” verdicts and mechanistic sentences are all stripped; only the labelled agent class remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All eleven items retain their example drug lists; two lists are trimmed for the page budget (hepatotoxic botanicals, additive anti-inflammatory supplements) but neither is dropped. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies thirteen interactions and the section is correctly populated, not empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol bullets, with the meal-anchoring clause from the “Best time of day” bullet. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose range, formulation choice and dose splitting are the three decisions a reader must actually make; the remaining bullets are modifiers rather than actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry substantive ER-derived content; no placeholder text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Exactly the three intervals the ER’s “Time to effect” bullet names: joint pain, lipid/glycemic/inflammatory markers, and the cognitive trial. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Joint pain (the ER’s largest High-tier effect) first, the High-tier metabolic and inflammatory cluster second, Low-tier memory and attention last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans carry ER-derived content, including the 51–84 age range from the ER Therapeutic Protocol age bullet. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All seventeen items are the ER’s benefit headings, tier for tier. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 539–565). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; every Magnitude figure, certainty note and mechanistic sentence is dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER (5 / 7 / 3 / 2), so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten items are the ER’s risk headings, tier for tier. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 632–653). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; the ⚠️ Conflicted markers, Magnitude figures and case-series detail are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER (1 / 2 / 5 / 2), so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker names, targets and why-column text are taken from the ER Monitoring Protocol & Defining Success table. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine quantifiable rows are present (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase/bilirubin, high-sensitivity C-reactive protein, fasting glucose/glycated haemoglobin, fasting lipid panel, ferritin, haemoglobin/complete blood count, 24-hour urinary oxalate); the tenth ER row is the subjective joint pain score, correctly routed to Qualitative Assessment. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Reproduces the ER’s front-loaded cadence: baseline, liver panel at 6–8 weeks / 6 months / annually, markers at 12 weeks then 6–12 months, iron studies at 6 and 12 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All eight items come from that section — the subjective joint pain score table row plus the seven qualitative bullets that follow the table. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Eight of eight present: joint pain score, morning stiffness, activity-specific pain, anti-inflammatory drug reliance, post-exercise soreness, digestive comfort, mood and motivation, energy and exercise tolerance. |
Issues 02/09/2026 13:46
Pass rate 100.00%. No issues found.
Issues 02/09/2026 13:37
- 1.3 — Hedged dose claim strengthened: ER line 422 states “Integrative practitioners typically settle at 1,000–1,500 mg of a standardized 95% curcuminoid extract for joint and inflammatory indications”, but [action_1_sub] (QRS line 457) drops both the attribution and the hedge, presenting it as “the settled range for joint and inflammatory indications”.
Fixes 02/09/2026 13:37
- 1.3 — Hedged dose claim restored: Rewrote [action_1_sub] from “Standardized 95% curcuminoid extract, the settled range for joint and inflammatory indications” to “The range integrative practitioners typically settle at for a standardized 95% curcuminoid extract in joint and inflammatory indications”, restoring the ER’s attribution and hedge.
Issues 02/09/2026 13:29
- 1.1 / 1.3 — Lifespan qualifier dropped:
[at_a_glance](line 438) says “Nothing touches lifespan”, dropping the ER’s scope qualifier from “Nothing in the human literature touches lifespan” (ER line 556); the unqualified absolute contradicts the ER’s own finding that curcumin lengthens lifespan in roundworms and fruit flies (ER line 255) and the QRS’s own[benefits_speculative]entry “Lifespan extension” (line 561).
Fixes 02/09/2026 13:29
- 1.1 / 1.3 — Lifespan qualifier restored: Changed
[at_a_glance]from “Nothing touches lifespan.” to “Nothing in humans touches lifespan.”, restoring the ER’s scope qualifier so the sentence no longer contradicts the ER’s invertebrate lifespan finding or the QRS’s own Speculative benefit entry. The section remains within the 60-word budget.
Issues 02/09/2026 13:22
- 1.1 / 1.3 — Phospholipid half-life upper bound dropped: [action_3_sub] (line 486–488) states “plasma half-life is roughly 1–2 hours against 6–8 hours for phospholipid forms”, but the ER (line 432) says “up to 6–8 hours for phospholipid forms”; removing “up to” turns a ceiling into a point estimate and strengthens the claim beyond what the ER literally supports.
Fixes 02/09/2026 13:22
- 1.1 / 1.3 — Phospholipid half-life upper bound restored: [action_3_sub] now reads “roughly 1–2 hours against up to 6–8 hours for phospholipid forms” instead of “against 6–8 hours”, restoring the ER’s “up to” ceiling so the figure is no longer stated as a point estimate.